Protocol Title: Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) including Patients of African Ancestry and Non-African Ancestry

Target Population: Triple-Negative Breast Cancer (TNBC)

Summary: CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with Paclitaxel in patients of African ancestry and non-African ancestry with advanced Triple Negative Breast Cancer. Multiple single-arm cohorts will be enrolled in which 800 mg BID CB-839 will be administered in combination with the full approved dose of Paclitaxel.

Key Inclusion Criteria:
- Meets criteria for 1 of the 4 defined study cohorts.
  - Cohort 1 – African Ancestry with 3rd Line+ Metastatic:
    - Patients must self-identify as African Ancestry.
    - At least 2 prior lines of systemic therapy for advanced/metastatic disease including a Taxane.
      - Prior Taxane (Paclitaxel, Docetaxel, or Nab-Paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.
      - Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 Months.
  - Cohort 2 – African Ancestry 1st Line Metastatic:
    - Patients must self-identify as African ancestry.
    - No prior systemic therapy for advanced or metastatic disease.
    - Systemic neoadjuvant or adjuvant therapy, including Taxane, is allowed if time to recurrence was > 12 Months.
  - Cohort 3 – Non-African Ancestry 3rd Line+ Metastatic:
    - Patients do not self-identify as African ancestry.
    - Otherwise have the same criteria as Cohort 1.
  - Cohort 4 – Non-African Ancestry 1st Line Metastatic:
    - Patients do not self-identify as African ancestry.
    - Otherwise have the same criteria as Cohort 2.
- TNBC defined as ER and PR Negative (<1%) and HER-2 Negative (FISH Negative or IHC 0-1+).
- Metastatic disease or locally-advanced disease not amenable to curative intent treatment.
- Adequate hepatic, renal, cardiac, and hematologic function.
- ECOG Performance Status 0-1.
- Recovery to baseline or ≤ Grade 1 CTCAE ver.4.0.

Key Exclusion Criteria:
- Known Brain Metastases or CNS Cancer unless adequately treated with radiotherapy and/or surgery and stable for ≥ 2 Months.
- Known hypersensitivity to Cremophor®-based agents.
- Major surgery within 28 Days of C1D1.

Contacts:
- Principal Investigator: John Cole, MD
- Research Nurses (RN): Amanda Woolery (amanda.woolley@ochsner.org, ext. 20275)
  Socea May (smay@ochsner.org, ext. 22373)

For additional information: https://clinicaltrials.gov/ct2/show/NCT03057600

IRB# 2017.123.B